These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14684154)

  • 1. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.
    Miyakawa Y; Ohnishi Y; Tomisawa M; Monnai M; Kohmura K; Ueyama Y; Ito M; Ikeda Y; Kizaki M; Nakamura M
    Biochem Biophys Res Commun; 2004 Jan; 313(2):258-62. PubMed ID: 14684154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
    Huang SY; Tien HF; Su FH; Hsu SM
    Am J Pathol; 2004 Feb; 164(2):747-56. PubMed ID: 14742278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.
    Huang YW; Richardson JA; Tong AW; Zhang BQ; Stone MJ; Vitetta ES
    Cancer Res; 1993 Mar; 53(6):1392-6. PubMed ID: 8443818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engraftment of peripheral blood mononuclear cells from human T-lymphotropic virus type 1 carriers in NOD/SCID/gammac(null) (NOG) mice.
    Takajo I; Umeki K; Morishita K; Yamamoto I; Kubuki Y; Hatakeyama K; Kataoka H; Okayama A
    Int J Cancer; 2007 Nov; 121(10):2205-11. PubMed ID: 17657714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
    Schueler J; Wider D; Klingner K; Siegers GM; May AM; Wäsch R; Fiebig HH; Engelhardt M
    PLoS One; 2013; 8(11):e79939. PubMed ID: 24223204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
    Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M
    Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rγ
    Yasuda M; Ogura T; Goto T; Yagoto M; Kamai Y; Shimomura C; Hayashimoto N; Kiyokawa Y; Shinohara H; Takahashi R; Kawai K
    Exp Anim; 2017 Oct; 66(4):425-435. PubMed ID: 28679969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of animal models in multiple myeloma.
    Libouban H
    Morphologie; 2015 Jun; 99(325):63-72. PubMed ID: 25898798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB.
    Dewan MZ; Terashima K; Taruishi M; Hasegawa H; Ito M; Tanaka Y; Mori N; Sata T; Koyanagi Y; Maeda M; Kubuki Y; Okayama A; Fujii M; Yamamoto N
    J Virol; 2003 May; 77(9):5286-94. PubMed ID: 12692230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of multiple myeloma mouse models expressing brain derived neurotrophic factor].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):967-72. PubMed ID: 17956671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
    Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
    Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of human Graafian follicles following transplantation of human ovarian tissue into NOD/SCID/gammac null mice.
    Terada Y; Terunuma-Sato Y; Kakoi-Yoshimoto T; Hasegawa H; Ugajin T; Koyanagi Y; Ito M; Murakami T; Sasano H; Yaegashi N; Okamura K
    Am J Reprod Immunol; 2008 Dec; 60(6):534-40. PubMed ID: 19032615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice).
    Watanabe Y; Takahashi T; Okajima A; Shiokawa M; Ishii N; Katano I; Ito R; Ito M; Minegishi M; Minegishi N; Tsuchiya S; Sugamura K
    Int Immunol; 2009 Jul; 21(7):843-58. PubMed ID: 19515798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an in vivo model of human multiple myeloma bone disease.
    Alsina M; Boyce B; Devlin RD; Anderson JL; Craig F; Mundy GR; Roodman GD
    Blood; 1996 Feb; 87(4):1495-501. PubMed ID: 8608240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
    Mitsiades CS; Mitsiades NS; Bronson RT; Chauhan D; Munshi N; Treon SP; Maxwell CA; Pilarski L; Hideshima T; Hoffman RM; Anderson KC
    Cancer Res; 2003 Oct; 63(20):6689-96. PubMed ID: 14583463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple integrations of human T-lymphotropic virus type 1 proviruses in the engrafted cells from the asymptomatic carriers in NOD/SCID/gammacnull mice.
    Yamamoto I; Takajo I; Umeki K; Morishita K; Hatakeyama K; Kataoka H; Nomura H; Okayama A
    Intervirology; 2010; 53(4):229-39. PubMed ID: 20357492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.
    Tsunenari T; Koishihara Y; Nakamura A; Moriya M; Ohkawa H; Goto H; Shimazaki C; Nakagawa M; Ohsugi Y; Kishimoto T; Akamatsu K
    Blood; 1997 Sep; 90(6):2437-44. PubMed ID: 9310495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
    Yaccoby S; Barlogie B; Epstein J
    Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.